Bococizumab is a promising novel monoclonal antibody designed to target and inhibit the activity of PCSK9. This targeted approach intends to lower levels of low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia, a condition characterized by elevated blood cholesterol. By blocking the action of PCSK9, bococizumab impedes